Botox for a gummy smile: when the dental assessment changes the answer

Botulinum toxin may temporarily reduce excessive gingival display when upper-lip muscle activity is an appropriate target, but it does not correct every cause of a “gummy smile.” Gummy-smile treatment is not an FDA-approved indication for BOTOX Cosmetic. A useful consultation first separates lip movement from gum, tooth, and skeletal relationships, then explains whether an off-label injection addresses the identified cause.¹²³

Start with what becomes visible when you smile

“Too much gum” is a description of appearance, not a complete treatment diagnosis. The same visible concern can arise through different relationships between the upper lip, tooth crowns, gum margin, bite, and upper jaw. More than one contributor can be present.

A dental assessment can change the proposed treatment because changing muscle activity is different from changing tissue position or tooth relationships. The orthodontic and surgical literature organizes interventions around the underlying finding rather than a universal injection plan.³

Ask the clinician to explain the observation in ordinary language. Is the upper lip moving farther than expected? Is gum covering more of the tooth crown? Is tooth position or jaw structure relevant? Which finding is dominant, and what remains uncertain? The answer should describe your examination, not merely repeat a package name.

Give each possible intervention a specific job

This is a consultation map, not a method for diagnosing a smile from photographs. It helps you ask why a particular professional is involved and which observation justifies each proposed step.

Choosing no treatment is also a legitimate option. Aesthetic preferences vary, and visible gingiva alone does not establish that a procedure is needed.

Off-label status belongs in the explanation

The current BOTOX Cosmetic label identifies specific adult cosmetic indications, including glabellar, lateral canthal, and forehead lines and platysma bands. Excessive gingival display is not among them.¹ An authentic FDA-approved product therefore does not make this particular use FDA approved.

Off-label is not a synonym for counterfeit or an assertion that a use is automatically unlawful. It means the proposed use departs from the product’s approved labeling. The off-label explainer separates those questions in more detail.

For this consultation, ask for the exact product, proposed purpose, relevant evidence, risks, alternatives, and the clinician’s reason for choosing it. Avoid translating an online dose or placement diagram into a personal plan. Product units and anatomy require professional assessment.

Temporary evidence is different from a promised result

A meta-analysis included 17 studies of botulinum toxin for excessive gingival display. It found a reduction that changed over follow-up, with substantial variation between studies and a tendency toward baseline as time passed.² That supports discussing a temporary effect, not guaranteeing a particular number of millimeters or a fixed duration for an individual.

Study measurements can differ by smile instruction, photographs, baseline severity, cause, product, and follow-up. A maximum posed smile and a spontaneous smile are not interchangeable endpoints. Ask what the practice will document at baseline and how it will repeat that observation afterward.

If evidence is presented as “works for gummy smiles,” ask which patients were included. A study in selected muscle-related cases cannot establish equal usefulness for every gingival, dental, or skeletal pattern. Likewise, short-term improvement does not answer the long-term burden of repeated treatment.

A lip flip is not the same consultation

A lip-flip appointment and a gummy-smile appointment may both involve a neuromodulator near the mouth, but the desired change differs. Do not assume a plan for visible lip shape answers a question about gingival display. The lip-flip comparison covers that separate decision.

Ask the injector to describe both the intended movement change and the functions that must be preserved. Discuss eating, drinking, speaking, smiling, and pre-existing asymmetry in the clinician’s assessment. The product label’s warnings remain relevant even when the cosmetic goal sounds small.¹

If multiple services are proposed, request a staged explanation: what is being assessed first, what would count as a satisfactory result, and what finding would lead to a different specialist instead of more injection. A combined package should not erase the distinct reason for each step.

Leave with a cause-to-plan explanation

A strong consultation produces more than a price. You should understand the main contributor to the visible gum, the role of any dental referral, the exact off-label proposal, and the expected limits of a temporary muscle effect. Ask how the practice handles an unwanted change and who performs the follow-up assessment.

When comparing providers, use Treomark’s neuromodulator listings as a discovery surface, then verify the treating professional and actual service. A listing for neuromodulators does not establish experience with this particular indication.

The decisive question is: “What finding explains my gingival display, and which part of that finding would this treatment actually change?” That answer determines whether an injection discussion is well matched—or whether another evaluation should come first.